PTN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 09:38):

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States...

Stats
Today's Volume	13 357.00
Average Volume	697 461
Market Cap	27.75M
EPS	$-0.560 ( 2024-02-15 )
Next earnings date	( $-0.660 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.580
ATR14	$0.00700 (0.41%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Deveer Robert K Jr	Buy	6 000	Common Stock
2024-03-06	Deveer Robert K Jr	Sell	1 685	Common Stock
2024-03-06	Deveer Robert K Jr	Sell	7 286	Common Stock
2024-03-06	Deveer Robert K Jr	Sell	200	Common Stock
2024-03-06	Deveer Robert K Jr	Sell	1 808	Common Stock

INSIDER POWER
46.95
Last 100 transactions
Buy: 594 391 \| Sell: 320 931

Volume Correlation

Long: -0.15 (neutral)

Short: 0.73 (moderate)

Signal:(35.436) Neutral

Palatin Technologies Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Palatin Technologies Inc Correlation - Currency/Commodity

0.17
( neutral )

0.26
( neutral )

0.00
( neutral )

0.35
( neutral )

0.28
( neutral )

0.48
( neutral )

Palatin Technologies Inc Financials

Annual	2023
Revenue:	$4.85M
Gross Profit:	$4.44M (91.38 %)
EPS:	$-2.53

Q2	2024
Revenue:	$2.03M
Gross Profit:	$1.77M (86.83 %)
EPS:	$-0.560

Q1	2024
Revenue:	$2.11M
Gross Profit:	$1.93M (91.65 %)
EPS:	$-0.480

Q4	2023
Revenue:	$1.76M
Gross Profit:	$1.66M (94.10 %)
EPS:	$-0.910

Financial Reports:

No articles found.

Palatin Technologies Inc

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.